High-throughput technologies exploited to analyze the mentioned tumor-related components that are released in the bloodstream could permit to: (i) have a complete genotyping of the entire tumor burden at the time of diagnosis; (ii) track clonal aberrations that characterize HGS-EOC such as TP53 mutations or 8q24 and 8q23 amplifications; and (iii) highlight tumor dynamic changes that occurs under a selective therapy pressure and obtain accurate information about the biology of relapse in order to guide the therapeutic decision [12,37]. Here, TP53 is linked to neoplasm.